Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 6
2021 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Heider M, Nickel K, Högner M, Bassermann F. Heider M, et al. Among authors: nickel k. Oncol Res Treat. 2021;44(12):672-681. doi: 10.1159/000520312. Epub 2021 Nov 8. Oncol Res Treat. 2021. PMID: 34749378 Free PMC article. Review.
[Important developments in the therapy of AML].
Nickel K. Nickel K. MMW Fortschr Med. 2023 Jan;165(1):36-39. doi: 10.1007/s15006-022-2177-0. MMW Fortschr Med. 2023. PMID: 36648670 Review. German. No abstract available.
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.
Petersohn S, McGregor B, Klijn SL, May JR, Ejzykowicz F, Kurt M, Dyer M, Malcolm B, Branchoux S, Nickel K, George S, Kroep S. Petersohn S, et al. Among authors: nickel k. J Comp Eff Res. 2023 Aug;12(8):e230004. doi: 10.57264/cer-2023-0004. Epub 2023 Jul 11. J Comp Eff Res. 2023. PMID: 37431849 Free PMC article. Review.
sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study.
Wimmer T, Mattes R, Stemmler HJ, Hauck F, Schulze-Koops H, Stecher SS, Starck M, Wendtner CM, Bojko P, Hentrich M, Nickel KE, Götze KS, Bassermann F, von Bergwelt-Baildon M, Spiekermann K. Wimmer T, et al. Among authors: nickel ke. Blood Adv. 2023 Mar 14;7(5):832-844. doi: 10.1182/bloodadvances.2022007953. Blood Adv. 2023. PMID: 35973195 Free PMC article.
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N, Decimoni TC, Dyer MTD, May JR, van de Wetering G, Petersohn S, Nickel K, Silva A, Muniz DQB, Casagrande D Oliveira AP. Dhanji N, et al. Among authors: nickel k. J Med Econ. 2023 Jan-Dec;26(1):1108-1121. doi: 10.1080/13696998.2023.2252716. J Med Econ. 2023. PMID: 37632452 Free article.
Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland.
Deeren D, Balabanov S, Nickel K, Giannopoulou C, Gonzalez-McQuire S, Kutikova L, Bouwmeester W, Spyridonidis A. Deeren D, et al. Among authors: nickel k. Leuk Res. 2020 Apr;91:106334. doi: 10.1016/j.leukres.2020.106334. Epub 2020 Feb 24. Leuk Res. 2020. PMID: 32135394 Free article.
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Steinhardt MJ, Zhou X, Krummenast F, Meckel K, Nickel K, Böckle D, Messerschmidt J, Knorz S, Dierks A, Heidemeier A, Lapa C, Einsele H, Rasche L, Kortüm KM. Steinhardt MJ, et al. Among authors: nickel k. Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420980258. doi: 10.1177/2058738420980258. Int J Immunopathol Pharmacol. 2020. PMID: 33353443 Free PMC article.
13 results